What are the statistics of pulmonary hypertension in Mexico?
Best insight from top research papers
Pulmonary hypertension (PH) is a significant health issue in Mexico. The prevalence of PH in the country is estimated to be around 1% of the population, with a higher prevalence in individuals aged over 65 years, reaching up to 10% . PH is associated with various underlying diseases, including left-sided heart and lung diseases, congenital heart disease, and infectious disorders such as schistosomiasis, HIV, and rheumatic heart disease . In specific PH subtypes, such as chronic thromboembolic pulmonary hypertension (CTEPH), the clinical experience in Mexico is limited due to resource limitations and lack of infrastructure for surgical interventions . The economic burden of managing pediatric pulmonary arterial hypertension (PAH) is also significant, with hospitalization and pharmacological treatment being areas with higher costs . Overall, there is a need for global research efforts to establish preventive strategies and treatments for the various types of PH, including in resource-limited settings like Mexico .
Answers from top 3 papers
More filters
| Papers (3) | Insight |
|---|---|
Open access•Journal Article | The paper does not provide statistics on pulmonary hypertension in Mexico. The paper discusses the obesity hypoventilation syndrome (OHS) and its association with pulmonary hypertension, but it does not provide specific statistics on the prevalence or incidence of pulmonary hypertension in Mexico. |
12 Citations | The paper does not provide statistics on pulmonary hypertension in Mexico. The paper is about the clinical experience of chronic thromboembolic pulmonary hypertension (CTEPH) in Mexico. |
| The paper does not provide statistics on the prevalence or incidence of pulmonary hypertension in Mexico. |
Related Questions
What are the latest research findings in pulmonary arterial hypertension?4 answersRecent research findings in pulmonary arterial hypertension (PAH) include advancements in transcriptomics and proteomics technology, which have provided new insights into the disease and identified novel gene targets involved in its development. A pilot study explored the relationship between patient-reported outcome measures (PROs), burden of illness assessment, and risk stratification criteria, revealing that PRO indices showed little correlation with established risk stratification markers. Ongoing research aims to improve identification and diagnosis of PAH in patients with systemic sclerosis (SSc), as well as investigate novel therapies specifically for SSc-associated PAH. A systematic review of randomized control trials highlighted the potential of AMPK activators and BMP2 inhibitors as promising PAH modifying therapies, while also emphasizing the need for long-term studies to evaluate other potential treatments. Pharmacogenomic associations have been reported with certain PAH medications, explaining some of the variability in treatment response. These findings contribute to a better understanding of PAH and may lead to improved management and treatment strategies in the future.
How many incidents of pulmonary arterial hypertension in Brazil?3 answersPulmonary arterial hypertension (PAH) incidents in Brazil were reported in several studies. One study found that there were 370 PAH patients in Southern Brazil. Another study focused on the state of Bahia and identified 48 patients with PAH. A study conducted in Pernambuco reported 68 patients with schistosomiasis-associated PAH (Sch-PAH). The prevalence of PAH in Brazil was also mentioned in a study discussing the epidemiological profile of diseases in the country. However, the exact number of incidents of PAH in Brazil was not explicitly stated in any of the abstracts.
Are there any clinical trials occuring for pulmonary arterial hypertension in Mexico?3 answersClinical trials for pulmonary arterial hypertension (PAH) are occurring in Mexico. A panel of experts in the Mexican health system analyzed and discussed the indications and limitations for riociguat in PAH. They issued recommendations regarding the use of riociguat in PAH based on the results of several clinical studies. These recommendations provide guidance for the treatment of PAH in Mexico.
Are there any clinical drug trials for pulmonary arterial hypertension occurring in Mexico?3 answersYes, there are clinical drug trials for pulmonary arterial hypertension occurring in Mexico. A panel of experts in the Mexican health system issued recommendations for the use of riociguat in the treatment of pulmonary arterial hypertension. Additionally, a clinical trial conducted in Mexico City compared the effectiveness of the combination of enalapril and nifedipine versus empirical treatment for hypertension in patients with uncontrolled blood pressure. These trials demonstrate the ongoing efforts in Mexico to study and improve the treatment of pulmonary arterial hypertension.
What are the Metabolic disorders related pathways in Pulmonary Arterial Hypertension?3 answersMetabolic disorders related pathways in Pulmonary Arterial Hypertension (PAH) include: a shift in metabolism related to increased expression of pyruvate dehydrogenase kinase and pyruvate kinase, resulting in uncoupled glycolysis (Warburg metabolism); disruption of oxygen-sensing related to increased expression of hypoxia-inducible factor 1α, resulting in a state of pseudohypoxia; altered mitochondrial calcium homeostasis related to impaired function of the mitochondrial calcium uniporter complex; abnormal mitochondrial dynamics related to increased expression of dynamin-related protein 1 and its binding partners, and depressed expression of mitofusin 2; substantial remodeling of the citrate cycle, pyruvate metabolism, glycolysis/gluconeogenesis, and fructose and mannose pathways; abnormal nitric oxide signaling, glucose metabolism, fatty acid oxidation, and the TCA cycle; upregulation of glucose uptake, glycolysis, insulin resistance, sphingolipid S1P, PGE2, TXA2, leukotrienes, and glutaminolysis; and disordered fatty acid metabolism in lung endothelial cells and smooth muscle cells.
What are the risk factors for pulmonary hypertension in chronic obstructive disease?5 answersPulmonary hypertension (PH) is a complication of chronic obstructive pulmonary disease (COPD) that is associated with increased morbidity and mortality. Risk factors for PH in COPD include Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage, emphysema, PaCO2, NT-pro-BNP, red blood cell (RBC) distribution width-standard deviation (RDW-SD), and neutrophil/lymphocyte ratio (NLR). Endothelial dysfunction and pulmonary vessel remodeling are also important factors in the development of PH in COPD. Other potential risk factors include chronic hypoxemia, hospitalization in the previous year, and impaired exercise capacity. Early identification of high-risk phenotypes and timely intervention are crucial in managing PH in COPD. Further research is needed to better understand the underlying mechanisms and to develop specific and efficient treatment options for PH in COPD.